3 terminated, 2 active not recruiting, 1 completed, 1 enrolling by invitation. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Terminated 3, Active not recruiting 2, Completed 1, Enrolling by invitation 1 |
Follow Antibody-mediated Rejection: new trials by email Literature Review of Antibody-mediated Rejection trials Research Report on Antibody-mediated Rejection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) Felzartamab - Antibody-mediated Rejection, Microvascular Inflammation | Phase 3 | Enrolling by invitation | Biogen | 201 | 2026-04-16 | 2026-11-02 |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) Felzartamab, Placebo - Antibody-mediated Rejection | Phase 3 | Active not recruiting | Biogen | 132 | 2024-12-03 | 2026-06-05 |
| TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients Tocilizumab - Antibody-mediated Rejection | Phase 3 | Active not recruiting | Vastra Gotaland Region | 50 | 2022-02-01 | 2026-08-10 |
| Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Clazakizumab, Physiologic saline solution - Antibody-mediated Rejection | Phase 3 | Terminated | CSL Behring | 194 | 2019-10-14 | 2025-07-23 |
| Transplant Antibody-Mediated Rejection: Guiding Effective Treatments Rituximab, Methylprednisolone, Intravenous Immunoglobulin - Kidney Transplant Rejection, Antibody-mediated Rejection | Phase 3 | Terminated | Imperial College London | 3 | 2019-07-17 | 2025-04-13 |
| Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients C1-esterase inhibitor, Placebo - Antibody-mediated Rejection | Phase 3 | Terminated | CSL Behring | 63 | 2017-11-06 | 2022-07-29 |
| The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation Eculizumab - Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant | Phase 3 | Completed | Cedars-Sinai Medical Center | 36 | 2012-11-01 | 2021-05-03 |
Complement Component 3 Deficiency, Autosomal Recessive (1) · Ventricular Dysfunction, Left (1)
Cardiovascular Diseases (1) · Heart Diseases (1) · Ventricular Dysfunction (1)
felzartamab (2) · Complement C1 Inhibitor Protein (1) · Immunoglobulins, Intravenous (1) · Methylprednisolone (1) · Plasma Exchange (1) · Rituximab (1) · clazakizumab (1) · eculizumab (1) · tocilizumab (1)
Biogen (2) · CSL Behring (2) · Cedars-Sinai Medical Center (1) · Imperial College London (1) · Vastra Gotaland Region (1)
United States (5) · Spain (4) · Canada (3) · France (3) · Germany (3) · Australia (2) · Austria (2) · Belgium (2) · Czechia (2) · Netherlands (2) · New Zealand (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Brazil (1)
Jignesh Patel, M.D., Ph.D. (1) · Michelle Willicombe, MA MRCP MD (1) · Seema Baid-Agrawal, MD, FASN (1)
PMID 40444214, PMID 33251691, PMID 33332922, PMID 35497778, PMID 35969004, PMID 36550562, PMID 37182818, PMID 38519988, PMID 39102302, PMID 41430762
2018 (2), 2017 (1), 2019 (1)